Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Financing Activities (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Cash from Financing Activities data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 131.48% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $8.9 million, down 94.05%, while the annual FY2025 figure was $8.9 million, 94.05% down from the prior year.
  • Cash from Financing Activities reached $1.3 million in Q4 2025 per APLS's latest filing, up from $793000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $391.1 million in Q1 2023 and bottomed at -$15.9 million in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $65.5 million, with a median of $2.3 million recorded in 2021.
  • The widest YoY moves for Cash from Financing Activities: up 22982.35% in 2022, down 204.62% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $384.0 million in 2021, then tumbled by 104.15% to -$15.9 million in 2022, then soared by 75.46% to -$3.9 million in 2023, then dropped by 2.22% to -$4.0 million in 2024, then skyrocketed by 131.48% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $1.3 million in Q4 2025, $793000.0 in Q3 2025, and $6.6 million in Q2 2025.